

Company name: Quintra Medical - Website- www.quintra-medical.com*

CEO name - Eyal Sandach eyal@quintra-medical.com

Select a CATEGORY: Medical Devices

Select one SESSION per abstract from the list below *

Engineering the Beating System: Biology Meets Technology

You may delete the section instructions, leaving only the bolded bullet title.

Answers below should not exceed 60 words per question:

• **Executive Summary / Investment Rational:**

In Quintra Medical we are Curing the Incurable - Novel Epicardial Ablation to Eliminate Risk of Sudden Death Due to Brugada Syndrome

Quintra Medical is developing a transformative solution for Brugada Syndrome, a life-threatening cardiac disorder affecting millions worldwide. Our innovative percutaneous epicardial ablation system addresses a critical unmet need in the treatment of this deadly arrhythmia.

Our team brings together world-class expertise in cardiac electrophysiology, medical device development, and successful commercialization. With proven track records at leading companies and regulatory agencies, we are uniquely positioned to deliver this transformative technology to market

• **Core Technology:**

Quintra Medical has developed a percutaneous epicardial ablation system that provides a minimally invasive approach to directly ablate the arrhythmogenic substrate in the RVOT epicardium

Key Value Propositions:

- **Curative Potential:** First treatment to address the root cause of Brugada Syndrome
- **Eliminates ICD Therapy Need:** Prevents painful shocks and long-term device dependency
- **Minimally Invasive Procedure:** Percutaneous approach reduces surgical risks and recovery time
- **Quality of Life Improvement:** Dramatic enhancement in patient wellbeing and peace of mind

- **Product Profile/Pipeline:**

Quintra groundbreaking technology offers the first curative treatment option for Brugada Syndrome patients. The Quintra Procedure also enables efficient screening and treatment of patients at risk (such as immediate family members of SCD victims)

- **Business Strategy:**

Quintra is developing one platform, three functions, redefining arrhythmia therapy.

Built for Brugada, scalable to broader SCD and systemic diseases.

We are in the R&D stage with sites in Israel and in the US. Raising our seed round with J&J as lead investor